Clinical trial
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I…
NCT00054158 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00054158 |
|---|---|
| Title | Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma |
| Official title | A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM) |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | dexamethasone, doxorubicin hydrochloride, thalidomide, vincristine sulfate |
| Enrollment | 24 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2006 |
| First posted | Feb 6, 2003 |
| Last update posted | Oct 3, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: